Study summary

A triple-hormone injection lowered HbA1c by about 2 points and weight by 15%

TRANSCEND-T2D-1 trial (retatrutide) · 537 people, phase 3 · Published June 2026, The Lancet

15.3%weight loss with the highest dose, vs 2.6% with placebo

What was tested

Retatrutide, a weekly injection that acts on GIP, GLP-1 and glucagon receptors, against placebo for 40 weeks in type 2 diabetes managed with diet and exercise.

What they found

What it means

Retatrutide may offer the largest blood sugar and weight effects of any diabetes drug so far.

Lancet, via PubMed ↗ Trial record NCT06354660 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.